インターロイキン-23
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2021/06/26 16:34 UTC 版)
インターロイキン-23（英: interleukin-23、略称: IL-23）は、IL12B（IL-12p40）サブユニット（IL-12と共通）とIL23A（IL-23p19）サブユニットから構成されるヘテロ二量体型サイトカインであり[1]、Th17細胞の維持と増殖に重要なサイトカインである。IL-23はIL-12ファミリーのサイトカインである[2]。IL-23に対する機能的な受容体は同定されており、IL-12Rβ1とIL-23Rから構成される[3]。分裂促進因子によって活性化されたリンパ球では、IL-23Rには24種類のスプライシングバリアントが存在し[4]、またIL-23結合ドメインの一塩基多型によってもTh17細胞の活性化能に差異が生じる[5]。アドネクチン-2（Adnectin-2）はIL-23に結合し、IL-23/IL-23Rと競合する[6]。
- ^ a b “Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12”. Immunity 13 (5): 715–25. (November 2000). doi:10.1016/S1074-7613(00)00070-4. PMID 11114383.
- ^ a b “Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)”. ImmunoTargets and Therapy 4: 185–90. (2015-10-01). doi:10.2147/ITT.S62870. PMC: 4918258. PMID 27471723.
- ^ “A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R”. Journal of Immunology 168 (11): 5699–708. (June 2002). doi:10.4049/jimmunol.168.11.5699. PMID 12023369.
- ^ “Identification and characterization of multiple splice forms of the human interleukin-23 receptor alpha chain in mitogen-activated leukocytes”. Genes and Immunity 9 (7): 631–9. (October 2008). doi:10.1038/gene.2008.64. PMID 18754016.
- ^ “The human IL-23 receptor rs11209026 A allele promotes the expression of a soluble IL-23R-encoding mRNA species”. Journal of Immunology 194 (3): 1062–8. (February 2015). doi:10.4049/jimmunol.1401850. PMID 25552541.
- ^ a b “Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics”. Expert Review of Proteomics 12 (2): 159–69. (April 2015). doi:10.1586/14789450.2015.1018897. PMC: 4409866. PMID 25711416.
- ^ a b c “Interleukin-23: as a drug target for autoimmune inflammatory diseases”. Immunology 135 (2): 112–24. (February 2012). doi:10.1111/j.1365-2567.2011.03522.x. PMC: 3277713. PMID 22044352.
- ^ “ILC3 function as a double-edged sword in inflammatory bowel diseases”. Cell Death & Disease 10 (4): 315. (April 2019). doi:10.1038/s41419-019-1540-2. PMC: 6453898. PMID 30962426.
- ^ “Regulation of Memory T Cells by Interleukin-23”. International Archives of Allergy and Immunology 169 (3): 157–62. (2016). doi:10.1159/000445834. PMID 27100864.
- ^ “IL-23 promotes tumour incidence and growth”. Nature 442 (7101): 461–5. (July 2006). Bibcode: 2006Natur.442..461L. doi:10.1038/nature04808. PMID 16688182.
- ^ “Type I cytokine profiles of human naïve and memory B lymphocytes: a potential for memory cells to impact polarization”. Immunology 118 (1): 66–77. (May 2006). doi:10.1111/j.1365-2567.2006.02342.x. PMC: 1782263. PMID 16630024.
- ^ “Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells”. The Journal of Biological Chemistry 276 (40): 37692–9. (October 2001). doi:10.1074/jbc.M105927200. PMID 11477091.
- ^ “Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis”. The Journal of Allergy and Clinical Immunology 134 (2): 373–81. (August 2014). doi:10.1016/j.jaci.2014.04.022. PMID 24910175.
- ^ “Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation”. Nature 510 (7503): 157–61. (June 2014). Bibcode: 2014Natur.510..157R. doi:10.1038/nature13199. PMC: 4127885. PMID 24759321.
- ^ “Elevations of novel cytokines in bacterial meningitis in infants”. PLOS ONE 13 (2): e0181449. (2018-02-02). Bibcode: 2018PLoSO..1381449S. doi:10.1371/journal.pone.0181449. PMC: 5796685. PMID 29394248.
- ^ “Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12”. The Journal of Experimental Medicine 181 (1): 381–6. (January 1995). doi:10.1084/jem.181.1.381. PMC: 2191822. PMID 7528773.
- ^ “Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12”. The Journal of Clinical Investigation 110 (4): 493–7. (August 2002). doi:10.1172/JCI15751. PMC: 150420. PMID 12189243.
- ^ “paratuberculosis Drives an Innate Th17-Like T Cell Response Regardless of the Presence of Antigen-Presenting Cells” (英語). Frontiers in Veterinary Science 7: 108. (2020). doi:10.3389/fvets.2020.00108. PMC: 7089878. PMID 32258066.
- ^ “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain”. Nature 421 (6924): 744–8. (February 2003). Bibcode: 2003Natur.421..744C. doi:10.1038/nature01355. PMID 12610626.
- ^ “Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation”. The Journal of Experimental Medicine 198 (12): 1951–7. (December 2003). doi:10.1084/jem.20030896. PMC: 2194162. PMID 14662908.
- ^ “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6”. The Journal of Clinical Investigation 116 (5): 1310–6. (May 2006). doi:10.1172/JCI21404. PMC: 1451201. PMID 16670770.
- ^ “IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis”. The Journal of Experimental Medicine 203 (11): 2485–94. (October 2006). doi:10.1084/jem.20061082. PMC: 2118119. PMID 17030948.
- ^ “Interleukin-23 drives innate and T cell-mediated intestinal inflammation”. The Journal of Experimental Medicine 203 (11): 2473–83. (October 2006). doi:10.1084/jem.20061099. PMC: 2118132. PMID 17030949.
- ^ “IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis”. The Journal of Experimental Medicine 203 (12): 2577–87. (November 2006). doi:10.1084/jem.20060244. PMC: 2118145. PMID 17074928.
- ^ “Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor”. Carcinogenesis 34 (3): 658–66. (March 2013). doi:10.1093/carcin/bgs384. PMID 23250909.
- ^ “Prognostic value of serum soluble interleukin-23 receptor and related T-helper 17 cell cytokines in non-small cell lung carcinoma”. Cancer Science 111 (4): 1093–1102. (April 2020). doi:10.1111/cas.14343. PMC: 7156824. PMID 32020720.
- ^ “Ustekinumab”. mAbs 1 (3): 216–21. (2009). doi:10.4161/mabs.1.3.8593. PMC: 2726595. PMID 20069753.
- ^ “Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis”. Journal of the American Academy of Dermatology 82 (5): 1138–1149. (May 2020). doi:10.1016/j.jaad.2019.12.038. PMID 31884091.
- ^ “Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12”. The Journal of Dermatological Treatment: 1–8. (April 2020). doi:10.1080/09546634.2020.1747592. PMID 32299269.
- ^ “Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage”. Prog. Neurobiol. 178: 101610. (March 2019). doi:10.1016/j.pneurobio.2019.03.003. PMID 30923023.
[続きの解説]
「インターロイキン-23」の続きの解説一覧
- 1 インターロイキン-23とは
- 2 インターロイキン-23の概要
- インターロイキン-23のページへのリンク
